Abstract
Background/aims
To evaluate the effects of botulinum toxin type A (BTX-A) treatment in patients with benign essential blepharospasm (BEB) by monitoring the ocular surface and ocular higher-order aberrations (HOAs) before and after treatment.
Methods
The present study reports a prospective case series of 38 patients (76 eyes, 11 men and 27 women; mean age 66.8 ± 9.8 years) with BEB who underwent BTX-A treatment at Kokura Memorial Hospital between 2013 and 2014. Patients were evaluated for ophthalmoscopic findings, Schirmer I test, tear film break-up time (t-BUT), HOAs, fluctuation index (FI), stability index (SI) using a wavefront aberrometer, 15 subjective symptoms using the Dry Eye-Related Quality of Life Score (DEQS), and complications before and after the treatment.
Results
After BTX-A treatment, the Schirmer I test score improved significantly from 5.9 ± 5.4 to 8.7 ± 6.1 mm and t-BUT recovered from 5.2 ± 1.7 to 7.3 ± 1.7 s. HOAs were classified into four patterns: stable (60.5 %), small fluctuation (14.5 %), sawtooth (17.1 %), and reverse sawtooth (7.9 %), and they significantly reduced after the treatment. Only FI (not SI) showed a marked reduction, and the DEQS significantly improved from 44.7 ± 21.6 to 37.6 ± 21.0 after the treatment (p < 0.05). There were no complications during the observations.
Conclusion
BTX-A is a treatment with a high potential to improve ocular surface disorders induced by BEB.
Similar content being viewed by others
References
Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthalmic Plast Reconstr Surg. 1998;14:305–17.
Defazio G, Livrea P. Primary blepharospasm: diagnosis and management. Drugs. 2004;64:237–44.
Marsden CD. Blepharospasm–oromandibular dystonia syndrome (Brueghel’s syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry. 1976;39:1204–9.
Kerrison JB, Lancaster JL, Zamarripa FE, Richardson LA, Morrison JC, Holck DE, et al. Positron emission tomography scanning in essential blepharospasm. Am J Ophthalmol. 2003;136:846–52.
Suzuki Y, Mizoguchi S, Kiyosawa M, Mochizuki M, Ishiwata K, Wakakura M, et al. Glucose hypermetabolism in the thalamus of patients with essential blepharospasm. J Neurol. 2007;254:890–6.
Emoto H, Suzuki Y, Wakakura M, Horie C, Kiyosawa M, Mochizuki M, et al. Photophobia in essential blepharospasm—a positron emission tomographic study. Mov Disord Off J Mov Disord Soc. 2010;25:433–9. doi:10.1002/mds.22916.
Etgen T, Muhlau M, Gaser C, Sander D. Bilateral grey-matter increase in the putamen in primary blepharospasm. J Neurol Neurosurg Psychiatry. 2006;77:1017–20.
Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA. 1982;248:3160–4.
Obermann M, Yaldizli O, De Greiff A, Lachenmayer ML, Buhl AR, Tumczak F, et al. Morphometric changes of sensorimotor structures in focal dystonia. Mov Disord. 2007;22:1117–23.
Elston JS, Marsden CD, Grandas F, Quinn NP. The significance of ophthalmological symptoms in idiopathic blepharospasm. Eye. 1988;2(Pt 4):435–9.
Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51:767–72.
Tsubota K, Fujihara T, Kaido M, Mori A, Mimura M, Kato M. Dry eye and Meige’s syndrome. Br J Ophthal. 1997;81:439–42.
Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol. 1985;99:542–6.
Price J, O’Day J. A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin. J Clin Neuroophthalmol. 1993;13:67–71.
Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjogren’s syndrome: a preliminary report. J Rheumatol. 1997;24:1842–3.
Park DI, Shin HM, Lee SY, Lew H. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm. Acta Ophthalmol. 2013;91:e108–12. doi:10.1111/aos.12002.
Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol. 2014;157(591–7):e1–2. doi:10.1016/j.ajo.2013.11.014.
Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–73. doi:10.1002/mds.25475.
Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012;29:579–89. doi:10.1007/s12325-012-0033-9.
Wakakura M, Tsubouchi T, Inouye J. Etizolam and benzodiazepine induced blepharospasm. J Neurol Neurosurg Psychiatry. 2004;75:506–7.
Sakane Y, Yamaguchi M, Yokoi N, Uchino M, Dogru M, Oishi T, et al. Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire. JAMA Ophthalmol. 2013;131:1331–8. doi:10.1001/jamaophthalmol.2013.4503.
Koh S, Maeda N, Hori Y, Inoue T, Watanabe H, Hirohara Y, et al. Effects of suppression of blinking on quality of vision in borderline cases of evaporative dry eye. Cornea. 2008;27:275–8. doi:10.1097/ICO.0b013e31815be9c8.
Koh S, Maeda N, Hirohara Y, Mihashi T, Ninomiya S, Bessho K, Watanabe H, Fujikado T, Tano Y. Serial measurements of higher-order aberrations after blinking in normal subjects. Invest Ophthalmol Vis Sci. 2006;47:3318–24.
Koh S, Maeda N, Hirohara Y, Mihashi T, Bessho K, Hori Y, Inoue T, Watanabe H, Fujikado T, Tano Y. Serial measurements of higher-order aberrations after blinking in patients with dry eye. Invest Ophthalmol Vis Sci. 2008;49:133–8. doi:10.1167/iovs.07-0762.
Koh S, Maeda N, Ninomiya S, Watanabe H, Fujikado T, Tano Y, et al. Paradoxical increase of visual impairment with punctal occlusion in a patient with mild dry eye. J Cataract Refract Surg. 2006;32:689–91.
Victoria AC, Pino A. Botulinum toxin type a and its uses in dry eye disease. Plast Reconstr Surg. 2012;130:209e–10e. doi:10.1097/PRS.0b013e31825500ba.
Yokoi N, Georgiev GA. Tear-film-oriented diagnosis and therapy for dry eye. In: Yokoi N, editor. Dry eye syndrome: basic and clinical perspectives. London: Future Medicine Ltd.; 2013. p. 96–108.
Yabiku MM, Sartori Jde F, Sarraff EP, Osaki TH, Hossaka SK, Pereira CI, et al. Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin. Arq Bras Oftalmol. 2011;74:414–6 (in Portuguese).
Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32:1219–23. doi:10.1097/ICO.0b013e318294f97e.
Acknowledgments
We thank Dr. David Eve (University of South Florida, Tampa, FL, USA) for his critical advice, comments, and for editing the English of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Y. Isshiki, none; H. Ishikawa, none; O. Mimura, none.
About this article
Cite this article
Isshiki, Y., Ishikawa, H. & Mimura, O. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm. Jpn J Ophthalmol 60, 486–491 (2016). https://doi.org/10.1007/s10384-016-0469-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-016-0469-6